Please use this identifier to cite or link to this item:
http://cmuir.cmu.ac.th/jspui/handle/6653943832/51070Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Linda Aurpibul | en_US |
| dc.contributor.author | Thanyawee Puthanakit | en_US |
| dc.contributor.author | Thira Sirisanthana | en_US |
| dc.contributor.author | Virat Sirisanthana | en_US |
| dc.date.accessioned | 2018-09-04T04:51:09Z | - |
| dc.date.available | 2018-09-04T04:51:09Z | - |
| dc.date.issued | 2010-05-15 | en_US |
| dc.identifier.issn | 10584838 | en_US |
| dc.identifier.other | 2-s2.0-77951814475 | en_US |
| dc.identifier.other | 10.1086/652150 | en_US |
| dc.identifier.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77951814475&origin=inward | en_US |
| dc.identifier.uri | http://cmuir.cmu.ac.th/jspui/handle/6653943832/51070 | - |
| dc.description.abstract | Three years after measles, mumps, and rubella revaccination in 38 human immunodeficiency virus-infected children who had achieved immune recovery after antiretroviral therapy, the prevalence of protective antibody levels was 85% for measles, 61% for mumps, and 79% for rubella, compared with 88%, 84%, and 100%, respectively, 1 month after revaccination. © 2010 by the Infectious Diseases Society of America. All rights reserved. | en_US |
| dc.subject | Medicine | en_US |
| dc.title | Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy | en_US |
| dc.type | Journal | en_US |
| article.title.sourcetitle | Clinical Infectious Diseases | en_US |
| article.volume | 50 | en_US |
| article.stream.affiliations | Chiang Mai University | en_US |
| Appears in Collections: | CMUL: Journal Articles | |
Files in This Item:
There are no files associated with this item.
Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.